Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE).
BACKGROUND
'Precision oncology' can ensure the best suitable treatment at the right time by tailoring treatment towards individual patient and comprehensive tumour characteristics. In current molecular pathology, diagnostic tests which are part of the standard of care (SOC) only cover a limited part of the spectrum of genomic changes, and often are performed in an iterative way. This occurs at the expense of valuable patient time, available tissue sample, and interferes with 'first time right' treatment decisions. Whole Genome Sequencing (WGS) captures a near complete view of genomic characteristics of a tumour in a single test. Moreover, WGS facilitates faster implementation of new treatment relevant biomarkers. At present, WGS mainly has been applied in study settings, but its performance in a routine diagnostic setting remains to be evaluated. The WIDE study aims to investigate the feasibility and validity of WGS-based diagnostics in clinical practice.


METHODS
1200 consecutive patients in a single comprehensive cancer centre with (suspicion of) a metastasized solid tumour will be enrolled with the intention to analyse tumour tissue with WGS, in parallel to SOC diagnostics. Primary endpoints are (1) feasibility of implementation of WGS-based diagnostics into routine clinical care and (2) clinical validation of WGS by comparing identification of treatment-relevant variants between WGS and SOC molecular diagnostics. Secondary endpoints entail (1) added clinical value in terms of additional treatment options and (2) cost-effectiveness of WGS compared to SOC diagnostics through a Health Technology Assessment (HTA) analysis. Furthermore, the (3) perceived impact of WGS-based diagnostics on clinical decision making will be evaluated through questionnaires. The number of patients included in (experimental) therapies initiated based on SOC or WGS diagnostics will be reported with at least 3 months follow-up. The clinical efficacy is beyond the scope of WIDE. Key performance indicators will be evaluated after every 200 patients enrolled, and procedures optimized accordingly, to continuously improve the diagnostic performance of WGS in a routine clinical setting.


DISCUSSION
WIDE will yield the optimal conditions under which WGS can be implemented in a routine molecular diagnostics setting and establish the position of WGS compared to SOC diagnostics in routine clinical care.
['Samsom|Kris G|KG|', 'Bosch|Linda J W|LJW|', 'Schipper|Luuk J|LJ|', 'Roepman|Paul|P|', 'de Bruijn|Ewart|E|', 'Hoes|Louisa R|LR|', 'Riethorst|Immy|I|', 'Schoenmaker|Lieke|L|', 'van der Kolk|Lizet E|LE|', 'Retèl|Valesca P|VP|', 'Frederix|Geert W J|GWJ|', 'Buffart|Tineke E|TE|', 'van der Hoeven|Jacobus J M|JJM|', 'Voest|Emile E|EE|', 'Cuppen|Edwin|E|', 'Monkhorst|Kim|K|0000-0002-8690-3811', 'Meijer|Gerrit A|GA|']
D014408:Biomarkers, Tumor D000066491:Clinical Decision-Making D004273:DNA, Neoplasm D005240:Feasibility Studies D006801:Humans D025202:Molecular Diagnostic Techniques D009369:Neoplasms D064887:Observational Studies as Topic D018579:Patient Selection D057285:Precision Medicine D012107:Research Design D013048:Specimen Handling D059039:Standard of Care D013673:Technology Assessment, Biomedical D000073336:Whole Genome Sequencing D057188:Workflow
Whole genome sequencing Diagnostics Cancer Biomarker Personalized medicine